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Abstract: Ciprofloxacin, a fluoroquinolone antibiotic, is widely used for the treatment of bacterial
infection in humans due to its broad antibacterial spectrum. An excessive use or overdose of
ciprofloxacin on the other hand can cause several adverse effects not only to humans but also
to microorganisms. Unabsorbed ciprofloxacin in the body is mostly excreted through urine and
finally goes to the environment, providing a drug resistance pressure on bacteria. Hence a
simple and efficient detection method of ciprofloxacin is necessary, which, for example, can be
used to analyze ciprofloxacin content in urine. Although ciprofloxacin itself shows inherent
fluorescence, direct fluorescent detection of ciprofloxacin in raw urine sample is difficult due to
autofluorescence of urine by other components. Herein we report that a Tb(III) complex of DO3A
(1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) can be efficiently sensitized by ciprofloxacin to
emit luminescence separately from the urine autofluorescence wavelength region. Tb-DO3A shows
excellent sensitivity with a detection limit of three parts per billion in aqueous buffer solution. Further,
Tb-DO3A is used to detect ciprofloxacin with high sensitivity and selectivity in a raw urine sample
without any purification or separation procedures in the concentrations ranging from 1 µg·mL−1
to 50 µg·mL−1. The direct measurement of ciprofloxacin excreted in urine may be used to control
overdose of the drug.
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1. Introduction
Ciprofloxacin (Cipro), a third-generation synthetic fluoroquinolone antibiotic, is highly active
against a broad spectrum of gram-negative and gram-positive bacteria. It is widely used for
the treatment of infection caused by the bacteria that are resistant to other antibiotics including
aminoglycosides and β-lactams [1]. The primary target of Cipro is topoisomerase II (a DNA gyrase),
an essential bacterial enzyme that maintains super-helical twists in DNA [2]. The drug generally
binds to the A subunit of the bacterial enzyme DNA gyrase and blocks DNA replication, which leads
to rapid killing of bacteria through additional processes. Several side effects of Cipro as observed
in humans include DNA damage [3], severe liver damage [4], and hematuria [5]. Also, Cipro is
much less absorbed by the gastrointestinal tract in bioactive form than other fluoroquinolones [6].
Accordingly, the renal clearance of Cipro exceeds normal glomerular filtration rates, leading to a higher
amount of renal tubular secretion to cause a relatively high Cipro concentration in urine [7]. A high
proportion of patients under treatment with Cipro experiences adverse reactions in the gastrointestinal
tract (nausea, vomiting), skin or the central nervous system. Such adverse effects and toxicities
are occasionally worrisome in case of overdose or excessive use of the antibiotics [8]. Accordingly,
determination of toxicities associated with higher doses and longer duration of therapy with Cipro
and other fluoroquinolones needs additional studies.
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At the same time, there is an increasing concern about bacterial resistance to antibiotics including
Cipro, by means of mutations of altering the A subunit of DNA gyrase and other processes such
as decreased drug permeation [9]. It is also observed that after oral administration, most of the
antibiotics including Cipro are partially metabolized and mostly released via patient excreta into the
municipal sewage system. If they are not eliminated during sewage treatment, the drugs that are
released into the effluent enter the aquatic environment and eventually reach drinking water. If the
concentrations of such antibiotics are high enough, effluent from hospitals, municipal sewage and
sewage treatment plants may become a reservoir of bacteria resistance to antibiotics. A few studies
showed that the amount of antibiotics emitted into hospital effluent is 10–20 times higher than the
MIC50 (minimum inhibitory concentrations) of susceptible pathogenic bacteria (i.e., 2 µg·L−1) [10].
The amount of antibiotics also frequently exceeds the MIC50 even in municipal sewage and surface
water. The presence of such a high amount of antibiotics in effluent and municipal sewage creates
a resistance pressure on bacteria. Accordingly, it is necessary to analyze regularly the amount of
drugs and active metabolites, especially the antibiotics adsorbed onto sewage sludge. Moreover,
fluoroquinolones are also widely used as veterinary drugs in food-producing animals. To reduce the
misuse of antibiotics, a regulation by the European Community has fixed a maximum residue limit
(MRL) in edible animal products for some fluoroquinolones such as enorfloxacin and Cipro, which is
settled at 30 µg·kg−1 for several edible animal tissues [11]. As the high risk of bacterial resistance could
be a clinical issue, efficient analytical techniques are required to monitor residue levels of antibiotics
such as Cipro in complex biological matrices.
Accordingly, several analytical methods have been reported for determining Cipro, which include high
performance liquid chromatography (HPLC), high performance thin layer chromatography [12–15].
Widely used HPLC methods for the determination of Cipro or similar fluoroquinolone derivatives in
biological material involve tedious extraction and clean-up steps prior to chromatography. As such,
these methods are also not suitable for high throughput analysis for a pharmacokinetic study.
The clinical significance of the potency and activities of Cipro in vivo depends on its pharmacology,
efficacy, and toxicity, which again depend on the bioavailability or achievable serum level upon
administration to body. Hence, there is a strong need to develop a new strategy towards the detection
and quantification of antibiotics, which could be readily applied to biological fluid samples.
In this purpose, fluorescent detection could be an ideal means due to its high sensitivity and
easy sample preparation procedures and non-invasive nature [16]. Cipro, being a representative
quinolone carboxylic acid derivative, shows native fluorescence emission at 440 nm (ΦF = 0.28) upon
excitation at 278 nm in water [13]. Based on the native fluorescence of Cipro, a number of detection
methods are reported such as spectrophotometry [17], spectrofluorimetry [18,19], and flow-injection
with chemiluminescence detection [20,21]. In those existing methods a sample separation process is
also necessary to remove proteins, amino acids and other biomolecules that interfere with the detection
signal. Accordingly, those methods are not applicable to intact biological samples due to the high
autofluorescence from the biological systems, the wavelengths of which overlap with that of Cipro
(350–500 nm). To avoid such interference, it is necessary to develop a detection system that signals in
the longer wavelength region.
In recent years, use of lanthanide complexes (especially Eu3+ and Tb3+), specifically sensitized
lanthanide luminescence, has been explored for the development of sensitive and selective detection
methods for biological analytes [22]. The main advantages of this technique include emission at the
longer wavelength, long luminescence life times, large Stokes shifts, and narrow emission bands,
the properties of which can be used to alleviate the scattering interference and the background
autofluorescence from the biomolecules. Cipro containing α-keto-acid functionality could chelate
with lanthanide ions and act as an antenna to transfer its emission energy to the lanthanide ion.
This sensitized emission with a large Stokes’ shift and narrow emission band in the longer wavelength
region is expected to enable us to detect Cipro in biological samples without any sample preparation
or pretreatment procedures. Nevertheless, only a few Ln3+-based fluorescent methods for Cipro
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detection are reported up to date, and those are often performed in conjunction with sample separating
techniques [13,21,23,24]. There are two reports on the terbium-sensitized luminescence detection of
ciprofloxacin or quinolone drugs, in which such sample extraction or separation procedures are not
performed [25,26]. One of the methods used a mixture of TbCl3 and a surfactant (SDBS: sodium
dodecylbenzene sulfonate) that enhanced terbium luminescence most effectively in its critical micelle
concentration [25]. The analytical performance of such a system is thus dependent on the ionic strength
of the medium. A background signal, that is, the Tb(III) emission, in the absence of a quinolone
(norfloxacin) drug is also observed. The other method used a polymeric nanoparticle system generated
from Tb(NO3)3·6H2O and adenine to detect Cipro in tablet and urine samples without complicated
sample pretreatment processes, but the luminescence measurement was performed in the time-gated
mode to avoid the autofluorescence/background signals from the samples [26]. For time-gated
luminescence measurement a special fluorimeter that uses a nitrogen laser source is needed. Therefore,
there is still a need to develop a convenient and reliable tool for the detection of quinolone antibiotics
in intact biological samples.
Herein, we disclose a simple and direct detection method of Cipro in a biological fluid (urine)
that does not require sample pretreatment or separation steps or a specialized fluorimeter, by further
exploring the sensitized lanthanide luminescence by Cipro. The method could be used to detect the
Cipro excreted in urine and hence to avoid the overdose of the drug. Also, the detection method
could be applied to detect Cipro in plasma to monitor its appropriate dosage and to understand drug
pharmacokinetics [27].
2. Results and Discussions
2.1. Ciprofloxacin Sensitized Lanthanide Luminescence
Among the lanthanides, europium ion (Eu3+) is well known for its characteristic red luminescence
at 615 nm and 591 nm, corresponding to the 5D0→ 7F2 and 5D0→ 7F1 transitions, respectively. Due to
the limitation of the direct excitation of Eu3+, a well-established phenomenon of using sensitized
excitation of Eu3+ is possible by an appropriate organic ligand through energy transfer [28]. According
to the Förster’s resonance energy transfer theory, the rate of energy transfer depends upon the extent of
overlap of the emission spectra of the donor with the excitation spectra of the accepter and the distance
between them [29]. At the same time as the energy transfer occurs from the triplet state of the sensitizer
to the lanthanide, an organic dye ligand with high population of the triplet state could serve as an
efficient sensitizer. Cipro has an intensely populated triplet state due to its relatively low energy gap
between the S1 and T1 states (11.9 kcal·mol−1) and shows high phosphorescence/fluorescence intensity
ratio (P/F = 2.92) [13]. So, a coordination complex of lanthanide ion with Cipro, upon excitation of
the Cipro moiety, would show a sensitized luminescence through the Förster’s resonance energy
transfer, where Cipro acts as energy donor and the lanthanide ion acts as energy acceptor. Keeping
this in mind, we evaluated several Eu3+ complexes with different number of free co-ordination sites
to find out the one that shows the largest sensitized luminescence change upon binding with Cipro.
We chose Eu-DOTA [DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid], Eu-DO3A
[DO3A = 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid)], and EuCl3 as the probe candidates,
which have the available co-ordination site number of one, two, and nine respectively for an analyte,
as the maximum co-ordination number for Eu3+ is nine (Figure 1).
One equivalent of Cipro was added to each of metal complexes in HEPES buffer (pH = 7.4),
and the luminescence from Eu3+ at 615 nm was monitored under excitation at 278 nm, a maximum
absorption wavelength of Cipro. A characteristic emission band of Eu3+ was observed only in the case
of Eu-DO3A among the three metal complexes examined (Figure 2a). It is thus concluded that Cipro
coordinates effectively only to Eu-DO3A, which has two vacant co-ordination sites, and Cipro acts
as the antenna molecule for the europium excitation. It is likely that the europium metal is bound
with Cipro by the two vacant co-ordination sites of the keto and carboxylate groups. Upon binding
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with Cipro, the coordination sites of Eu3+ in Eu-DO3A are saturated and thus there are no available
coordination sites for water molecules. Generally when a lanthanide ion forms a binary complex,
its coordination sphere is usually filled by water molecules; such bound water molecules have a
quenching effect on the lanthanide emission through vibrational relaxation [30].
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Figure 1. Structures of Eu3+ and Tb3+ complexes evaluated for the detection of ciprofloxacin (Cipro).
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To assess the sensitivity of Tb-DO3A, we measured the lower detection limit (LOD) of Cipro.
Tb-DO3A showed excellent sensitivity towards Cipro in HEPES buffer even at the concentration of
Cipro down to three parts per billion (9 pM) level, with the terbium emission signal (at 542 nm) to
noise ratio of more than three (Figure 5a).
Our final goal is to develop a simple detection system of Cipro in intact biological samples,
especially in urine samples. If we could measure the amount of excreted Cipro that was not absorbed
in the body after taking the drug, it would be possible to measure the drug bioavailability, i.e.,
an absorbed amount of Cipro in the body (by excluding the amount of excreted Cipro from the
amount of orally taken), which, in turn, could help us to control the dose of the drug and thus to
avoid overdose.
Prior to detection of Cipro in urine, we evaluated the selectivity of Tb-DO3A toward potentially
competing compounds remaining in urine. Among the normal compositions of urine [33], aspirin,
hippuric acid, and benzoic acid could act as sensitizers upon coordination with lanthanide ions.
Gratifyingly, Tb-DO3A shows excellent selectivity over these compounds, providing terbium
luminescence only in presence of Cipro but not in other cases (Figure 5b).
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Figure 5. (a) Emission changes of Tb-DO3A (5 µM) upon addition of Cipro (3 ppb). The fluorescence
data were obtained by excitation at 278 nm in HEPES buffer (pH = 7.4). This data shows a
signal-to-background ratio of more than three. (b) Selective luminescence response of Tb-DO3A
(10 µM) towards Cipro over other analytes possibly present in urine, such as aspirin, hippuric acid,
and benzoic acid. Each of the analytes was added at a concentration of 20 µM in HEPES Buffer
(pH = 7.4). The spectra were recorded under excitation at 278 nm.
2.3. Ciprofloxacin Detection in Urine Sample
Finally, we applied Tb-DO3A for the detection of Cipro in intact urine. To this end, urine from a
healthy volunteer was collected. The raw urine was diluted 10-times by adding DI water. Without any
other pretreatment, the diluted urine was directly used for the fluorimetric assay. Tb-DO3A was added
to a fixed volume of the diluted urine (2.5 mL) to make a final concentration of Tb-DO3A at 20 µM. Then
Cipro was spiked to that solution at various concentrations, ranging from 1 µg·mL−1 to 50 µg·mL−1,
with respect to the actual raw urine. It has been observed that urine itself shows strong autofluorescence
in the wavelength region of 300–475 nm, which remains merged with the native fluorescence of
Cipro (Figure 6a). This auto-fluorescence of urine samples is likely to be originated from the amino
acids, proteins and biomolecules present in the raw urine sample [33]. To remove this interfering
autofluorescence, most of the previous detection protocols based on Cipro’s native fluorescence were
performed after laborious sample preparation steps to remove those biomolecules and proteins from
urine [13,14,17–21,23,24]. Hence, those methods are not applicable to direct fluorimetric measurement
for biological samples. On the contrary, we can conduct the Cipro detection without any sample
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preparation steps, as the sensitized luminescence of Tb-DO3A shows distinct emission peaks only
in the presence of Cipro with little interference from other urine components (Figure 6a). Although
the native fluorescence of Cipro was completely buried under the auto-fluorescence of urine, still the
strong terbium luminescence peak at 542 nm (which is away from the urine auto-fluorescence region)
was clearly observed upon treatment with Tb-DO3A even in the lower concentration range of Cipro
(<10 mg·mL−1) (Figure 6b). The terbium luminescence increases linearly with the concentration of
Cipro (Figure 6c), which would provide a convenient way to determine the unknown concentration of
Cipro in urine samples. According to reported data, after oral administration of a Cipro tablet (250 mg)
by a healthy human, the minimum amount of intact Cipro excreted through urine is ~4 µg·mL−1,
which is dependent on the time and day of dose [27]. Our luminescence detection method using
Tb-DO3A shows high sensitivity even in a raw urine sample; hence, it is suitable for the detection of
such a low level of Cipro.
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Figure 6. (a) Full emission spectra of urine, urine treated with Tb-DO3A, and urine treated both with
Tb-DO3A and varying concentration of Cipro. The raw urine was diluted 10-times with DI-water.
Tb-DO3A was added at a fixed concentration of 20 µM. The Cipro was added at various concentrations
ranging from 1 µg·mL−1 to 50 µg·mL−1 with respect to the actual raw urine sample. The spectra
were recorded after excitation at 278 nm. (b) The terbium emissions observed at the lower Cipro
concentration region, which was produced from (a). (c) The linear intensity changes of terbium
emission at 542 nm with increasing concentrations of Cipro, as measured in urine sample.
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3. Experimental Section
3.1. Reagents and Solvents
Ciprofloxacin, europium chloride (EuCl3) and terbium nitrate (Tb(NO3)3) were purchased
from Sigma-Aldrich Chemicals. Eu-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
(Eu-DOTA) [34], Eu-(1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) (Eu-DO3A) [35] and
Tb-(1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) (Tb-DO3A) [36] were prepared by following the
literature procedures. All the solvents used were of analytical grade. Aqueous solutions were prepared
using deionized water produced by a Milli-Q water system (Millipore, Darmstadt, Germany).
3.2. Apparatus and Instruments
All the apparatus used for synthesis of ligands and preparation of analytical solutions were made
of Pyrex glass. A Photon Technical International Fluorescence system was used to record the emission
spectra. HP Agilent 8453 spectrophotometer was used to measure the absorption spectra. All pH
measurements were made with a pH meter of Thermo scientific, Orion 2 star pH benchtop.
3.3. Measurement Methods for the Detection of Ciprofloxacin
Solutions of the probes were prepared from the corresponding metal complexes by dissolving in
DI water to make a stock solution at a concentration of 1 mM. The required amount of stock solution
was added to 10 mM HEPES buffer (3 mL) of pH = 7.4 taken in a Quartz cuvette to prepare the probe
solutions of 10 µM. Stock solutions of ciprofloxacin were prepared in DI water at a concentration
of 0.5 mM. The required amount of ciprofloxacin stock solution was added gradually to the probe
solution (3 mL) in HEPES buffer (pH = 7.4) in the quartz cuvette to make various final concentrations
as needed. After each addition of ciprofloxacin, the emission spectra were recorded in the wavelength
regions of 350–750 nm under excitation at 278 nm.
3.4. Sample Treatment for the Determination of Ciprofloxacin in Urine
Urine from a healthy volunteer was collected. The raw urine sample was diluted ten times with DI
water. Without any other pretreatment, the diluted urine was directly used for the fluorimetric study.
Tb-DO3A was added to a fixed volume (2.5 mL) of the diluted urine to make the final concentration
of Tb-DO3A at 20 µM. A stock solution of Cipro (0.5 mM) in DI water was spiked to the solution at
various concentrations, ranging from 1 µg·mL−1 to 50 µg·mL−1, with respect to the raw urine sample.
After each addition, the emission spectra were measured upon excitation at 278 nm.
4. Conclusions
We have developed a simple yet efficient detection method for the antibiotic drug ciprofloxacin
(Cipro) in urine sample based on the sensitized lanthanide luminescence. Evaluation of Förster’s
resonance energy transfer efficiency between Cipro and several lanthanide complexes led to the
terbium complex of DO3A (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) as a simple yet efficient
detection system for Cipro. Non-luminescent Tb-DO3A emits characteristic terbium luminescence at
542 nm after binding to Cipro through the resonance energy transfer, enabling fluorescence detection
of Cipro in the long wavelength region necessary to avoid the autofluorescence of proteins and
biomolecules present in urine. The detection method is highly sensitive with a limit of detection down
to three parts per billion level of Cipro in buffer solution. Also, the detection method is highly selective
to Cipro over other potentially competing analytes in urine. Moreover, it is demonstrated that this
simple detection method can be used to measure the amount of Cipro in a urine sample without
any pretreatment or separation steps by using a common fluorimeter. The detection method could
be applied to measure the bioavailability of Cipro and hence to control drug overdose and to study
drug pharmacokinetics.
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